.jpg?format=webp&width=780)
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in flux toward niche applications, owing to recent paradigm shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. This Trial Watch summarizes the recent preclinical and clinical developments in this field and discusses the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.
Like
Save
Share